Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-05 20:33 | 2026-06-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | Director, Officer; CEO | Biological Products, (No Diagnostic Substances) | SALE | $2.70 | 15,380 | $41,543 | 248,313 | -5.8% |
| 2026-06-05 20:33 | 2026-06-03 | EDIT | Editas Medicine, Inc. | Parison Amy | Officer; SVP, Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $2.70 | 464 | $1,253 | 14,970 | -3.0% |
| 2026-06-05 20:15 | 2026-06-04 | KROS | Keros Therapeutics, Inc. | Seth Alpna | Director | Pharmaceutical Preparations | SALE | $10.72 | 2,625 | $28,140 | 9,767 | -21.2% |
| 2026-06-05 20:15 | 2026-06-03 | INSM | INSMED Inc | Adsett Roger | Officer; Chief Operating Officer | Pharmaceutical Preparations | SALE | $102.27 | 2,370 | $242,380 | 98,603 | -2.3% |
| 2026-06-05 20:19 | 2026-06-03 | ALDX | Aldeyra Therapeutics, Inc. | Brady Todd C | Director, Officer; President and CEO | Pharmaceutical Preparations | BUY | $1.67 | 250,000 | $418,450 | 1,721,298 | +17.0% |
| 2026-06-05 20:01 | 2026-06-03 | OCUL | OCULAR THERAPEUTIX, INC | Waheed Nadia | Officer; Chief Medical Officer | Pharmaceutical Preparations | SALE | $8.27 | 14,828 | $122,628 | 300,079 | -4.7% |
| 2026-06-05 17:46 | 2026-06-04 | PRTA | PROTHENA CORP PUBLIC LTD CO | SCULLY WILLIAM P | 10% owner | Pharmaceutical Preparations | BUY | $9.31 | 50,000 | $465,295 | 936,000 | +5.6% |
| 2026-06-04 20:05 | 2026-06-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $35.00 | 4,375 | $153,125 | 75,753 | -5.5% |
| 2026-06-04 20:05 | 2026-06-03 | MDWD | MediWound Ltd. | SHAMIR NACHUM | Director | Medicinal Chemicals & Botanical Products | BUY | $14.00 | 6,000 | $83,996 | 55,815 | +12.0% |
| 2026-06-05 00:35 | 2026-06-03 | GNLX | GENELUX Corp | Smalling Ralph | Officer; Head of Regulatory | Pharmaceutical Preparations | SALE | $2.93 | 192 | $563 | 67,611 | -0.3% |
| 2026-06-05 00:00 | 2026-06-02 | JANX | Janux Therapeutics, Inc. | Doyle Janeen Noel | Officer; Chief Corp. & Bus. Dev. Ofcr | Pharmaceutical Preparations | SALE | $14.03 | 4,059 | $56,944 | 75,941 | -5.1% |
| 2026-06-04 22:08 | 2026-06-04 | SMMT | Summit Therapeutics Inc. | DUGGAN ROBERT W | Director, Officer, 10% owner; Co-Chief Executive Officer | Pharmaceutical Preparations | BUY | $14.60 | 100,000 | $1,460,000 | 25,824,474 | +0.4% |
| 2026-06-04 22:02 | 2026-06-02 | NBIX | NEUROCRINE BIOSCIENCES INC | Cooke Julie | Officer; Chief Human Resources Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $156.22 | 36,937 | $5,770,235 | 22,374 | -62.3% |
| 2026-06-04 21:45 | 2026-06-04 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Director, Officer, 10% owner; Co-Chief Executive Officer | Pharmaceutical Preparations | BUY | $14.60 | 100,000 | $1,460,000 | 25,824,474 | +0.4% |
| 2026-06-04 21:30 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer; EVP & GENERAL COUNSEL | Pharmaceutical Preparations | OPT+S | $547.07 | 8,300 | $4,540,643 | 45,172 | -15.5% |
| 2026-06-04 21:04 | 2026-06-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Borgeson Blake | Director | Biological Products, (No Diagnostic Substances) | SALE | $3.68 | 30,000 | $110,400 | 6,169,863 | -0.5% |
| 2026-06-04 21:04 | 2026-06-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Bumpus Namandje | Director | Biological Products, (No Diagnostic Substances) | SALE | $3.54 | 4,386 | $15,526 | 43,171 | -9.2% |
| 2026-06-04 21:00 | 2026-06-04 | ALKS | Alkermes plc. | Gaffin David Joseph | Officer; EVP, CLO, Alkermes, Inc. | Pharmaceutical Preparations | SALE | $43.05 | 2,034 | $87,564 | 229,524 | -0.9% |
| 2026-06-04 20:40 | 2026-06-04 | SMMT | Summit Therapeutics Inc. | Soni Manmeet Singh | Director, Officer; COO and CFO | Pharmaceutical Preparations | BUY | $14.45 | 50,000 | $722,250 | 3,123,603 | +1.6% |
| 2026-06-04 20:49 | 2026-06-02 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $70.60 | 20,000 | $1,412,000 | 3,985 | -83.4% |
| 2026-06-04 20:30 | 2026-06-03 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $547.61 | 9,500 | $5,202,271 | 40,513 | -19.0% |
| 2026-06-04 20:00 | 2026-06-03 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Shields Matthew | Officer; EVP, Global Operations | Pharmaceutical Preparations | OPT+S | $32.87 | 16,195 | $532,330 | 9,989 | -61.9% |
| 2026-06-03 20:30 | 2026-06-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $98.69 | 11,430 | $1,128,080 | 85,533 | -11.8% |
| 2026-06-03 20:06 | 2026-06-01 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Liu Joy | Officer; EVP and Chief Legal Officer | Pharmaceutical Preparations | SALE | $439.91 | 828 | $364,245 | 19,959 | -4.0% |
| 2026-06-03 20:31 | 2026-06-01 | LQDA | Liquidia Corp | Krepp Sarah | Officer; Chief Human Resource Officer | Pharmaceutical Preparations | SALE | $60.87 | 276 | $16,800 | 146,743 | -0.2% |
| 2026-06-03 20:10 | 2026-06-01 | ONC | BeOne Medicines Ltd. | Yi Qingqing | Director | Pharmaceutical Preparations | SALE | $279.13 | 235 | $65,596 | 0 | -100.0% |
| 2026-06-03 20:59 | 2026-06-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer; CHIEF OPERATING OFFICER | Biological Products, (No Diagnostic Substances) | SALE | $49.52 | 2,250 | $111,416 | 158,494 | -1.4% |
| 2026-06-03 20:30 | 2026-06-01 | LQDA | Liquidia Corp | KIRSCH ARTHUR S | Director | Pharmaceutical Preparations | SALE | $57.71 | 30,000 | $1,731,300 | 0 | -100.0% |
| 2026-06-03 20:25 | 2026-06-01 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | PYOTT DAVID E I | Director | Pharmaceutical Preparations | OPT+S | $299.18 | 3,830 | $1,145,853 | 1,582 | -70.8% |
| 2026-06-04 01:30 | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $71.06 | 7,500 | $532,937 | 97,994 | -7.1% |
| 2026-06-04 01:31 | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $70.43 | 15,000 | $1,056,486 | 597,540 | -2.4% |
| 2026-06-04 01:32 | 2026-06-03 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Officer; Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $75.00 | 8,333 | $624,975 | 0 | -100.0% |
| 2026-06-04 00:30 | 2026-06-01 | REPL | Replimune Group, Inc. | Sarchi Christopher | Officer; Chief Commercial Officer | Biological Products, (No Diagnostic Substances) | SALE | $9.24 | 12,000 | $110,880 | 180,962 | -6.2% |
| 2026-06-04 00:06 | 2026-06-01 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer; PRESIDENT AND CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $67.40 | 50,000 | $3,370,010 | 767,780 | -6.1% |
| 2026-06-04 00:02 | 2026-06-01 | EVMN | Evommune, Inc. | Pena Luis C. | Director, Officer; President & CEO | Pharmaceutical Preparations | SALE | $22.74 | 16,787 | $381,736 | 637,896 | -2.6% |
| 2026-06-04 00:02 | 2026-06-01 | EVMN | Evommune, Inc. | Patel Jeegar Pravinkumar | Officer; Chief Scientific Officer | Pharmaceutical Preparations | OPT+S | $22.74 | 16,687 | $379,462 | 46,403 | -26.4% |
| 2026-06-04 00:03 | 2026-06-02 | EVMN | Evommune, Inc. | Cohen David E | Director | Pharmaceutical Preparations | SALE | $20.33 | 6,056 | $123,094 | 17,609 | -25.6% |
| 2026-06-03 23:20 | 2026-06-01 | CORT | CORCEPT THERAPEUTICS INC | Mokari Atabak | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $70.00 | 40,000 | $2,800,004 | 15,257 | -72.4% |
| 2026-06-03 23:20 | 2026-06-01 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer; See Remarks | Pharmaceutical Preparations | OPT+S | $70.21 | 25,000 | $1,755,183 | 8,977 | -73.6% |
| 2026-06-03 23:11 | 2026-06-01 | SEPN | Septerna, Inc. | Shaikhly Samira | Officer; Chief People Officer | Pharmaceutical Preparations | OPT+S | $28.93 | 5,935 | $171,682 | 793 | -88.2% |
| 2026-06-03 22:51 | 2026-06-01 | EXEL | EXELIXIS, INC. | Eckhardt Sue Gail | Director | Biological Products, (No Diagnostic Substances) | SALE | $50.14 | 9,812 | $491,974 | 16,079 | -37.9% |
| 2026-06-03 22:52 | 2026-06-01 | EXEL | EXELIXIS, INC. | WYSZOMIERSKI JACK L | Director | Biological Products, (No Diagnostic Substances) | SALE | $50.55 | 3,925 | $198,409 | 284,384 | -1.4% |
| 2026-06-03 22:37 | 2026-06-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer; President, R&D | Pharmaceutical Preparations | OPT+S | $22.87 | 27,000 | $617,571 | 115,743 | -18.9% |
| 2026-06-03 22:42 | 2026-06-01 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | Pharmaceutical Preparations | SALE | $0.46 | 139,803 | $63,624 | 482,776 | -22.5% |
| 2026-06-03 22:44 | 2026-06-01 | NATR | NATURES SUNSHINE PRODUCTS INC | Norman Daniel C | Officer; EVP & President, Asia | Pharmaceutical Preparations | SALE | $20.64 | 9,713 | $200,476 | 47,276 | -17.0% |
| 2026-06-03 22:03 | 2026-06-02 | OTLK | Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Director | Biological Products, (No Diagnostic Substances) | BUY | $0.83 | 29,000 | $24,145 | 66,167 | +78.0% |
| 2026-06-03 21:36 | 2026-06-02 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Saxena Nishant C | Officer; Chief Business Officer | Pharmaceutical Preparations | BUY | $7.50 | 13,500 | $101,219 | 75,300 | +21.8% |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Berkley Neil Lindsay | Officer; CFO & Chief Business Officer | Biological Products, (No Diagnostic Substances) | SALE | $1.97 | 19,360 | $38,221 | 379,900 | -4.8% |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Wong-Sarad Grace | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $1.94 | 9,184 | $17,813 | 95,461 | -8.8% |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Rosenthal Arnon | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | SALE | $1.97 | 87,216 | $172,191 | 2,367,206 | -3.6% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.